看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。! @/ X" q/ {9 B' B2 x, h, Y
1 F: A- Z6 z+ O: r: L
( A6 _( N+ ?) n% v/ P3 ?5 d: B: Z
Currently available feasibility data for possible combination strategies. - B% E& j8 G% Y7 ?
————————————————————————————————; n. c4 ^) u' F1 O# g ^ p
Combination Feasibility according to preliminary data
1 T) `- X. b, V& U% }——————————————————————————————————1 G' }; B3 O0 N2 z9 u" N+ W2 s
Bevacizumab + sorafenib Yes, reduced dose
6 w+ X: `( b6 k$ iBevacizumab + sunitinib† No
8 M" J0 H5 H" d |# `Bevacizumab + temsirolimus Yes . d' N6 Y3 ^: a. J
Bevacizumab + everolimus Yes
4 u+ Z2 p `/ c: \3 [Sorafenib + sunitinib ? * d+ `) s H* d
Sorafenib + temsirolimus Yes, reduced dose
3 e& J6 k/ Y) c9 vSorafenib + everolimus Yes, reduced dose
- U* V1 j6 [5 ?Sunitinib + temsirolimus† No 5 }3 v- t( Q7 V: ?% K
Sunitinib + everolimus ?
! s/ H' a7 L+ G! u! `& {Temsirolimus + everolimus ?
! P# C3 D6 d7 _: K; E3 ?1 p4 L3 S————————————————————
+ ^8 j6 Y7 U* K$ Y3 D, l1 z0 X†Led to US FDA warning.
2 _, I! h7 _! {( W/ t?: As yet unattempted combination.
4 K$ G9 z5 ^* I7 F |